Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (May 2023)

21 slides from Sernova Biotherapeutics's investor presentation, May 2023

  1. Slide 1: Advancing cell therapeutics to provide 'functional cures'

    Slide 1: Advancing cell therapeutics to provide 'functional cures'

    Advancing cell therapeutics to provide ‘functional cures’ Q2 2023 Corporate Presentation

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

  3. Slide 3: Capital Structure / Select Information

    Slide 3: Capital Structure / Select Information

    Capital Structure / Select Information EXCHANGE: 52-week Range 1 $0.69 - 2.22 TSX: SVA Shares Outstanding 303 million OTCQB: SEOVF Market Cap 1 $300 million FSE / XETRA: PSH Average Daily Volume 2 0.23 million Cash (1/31/23) $45.6 million FISCAL Y/E: 10/31 Debt $0 Analyst Coverage 1All figures as of

  4. Slide 4: Sernova: Innovator and Leader

    Slide 4: Sernova: Innovator and Leader

    Sernova: Innovator and Leader Cell Therapeutics: Paradigm Shift for Superior Treatment of High-Maintenance, Lifelong Conditions • Sernova’s integrated Cell Pouch System™ provides the potential for a ‘functional cure’ for chronic medical conditions with multi-billion dollar market potential • Cell Po

  5. Slide 5: Sernova's Integrated Cell Therapeutics Solution

    Slide 5: Sernova's Integrated Cell Therapeutics Solution

    Sernova’s Integrated Cell Therapeutics Solution • 1st generation utilizes human donor cells • Proprietary implantable medical device • 2nd generation off-the-shelf stem cell derived cells • Provides vascularized environment for therapeutic cells to survive for long periods • i.e. Evotec iPSC islet o

  6. Slide 6: Pipeline – Life Cycle Iterations and Multiple Indications

    Slide 6: Pipeline – Life Cycle Iterations and Multiple Indications

    Pipeline – Life Cycle Iterations and Multiple Indications Lead Program Has Demonstrated POC Efficacy & Excellent Safety in Type 1 Diabetes Product Therapeutic Candidate Indication Cell Source Immune Protection Discovery Pre-Clinical Phase 1/2 Phase 3 BLA Human donor Immunosuppressives islet cells Ce

  7. Slide 7: Diabetes Global Disease = Global Market

    Slide 7: Diabetes Global Disease = Global Market

    DIABETES GLOBAL DISEASE = GLOBAL MARKET Diabetes is one of the most prevalent diseases and most pervasive medical problems impacting society and quality of life today. 537 million people are affected worldwide with diabetes; another estimated 179 million people have it without knowing it. By 2045, p

  8. Slide 8: The Advantages of Pancreatic Islets

    Slide 8: The Advantages of Pancreatic Islets

    The Advantages Of Pancreatic Islets Over ed ° Alpha Cells Beta Cells Insulin : : Injection Pancreatic Islets: The Complete Approach lets global regula\ Sernova’s Cell Pouch System™ Evotec is manufactur tic islet-ike clusters (ILCs) that mimic the funct n islets. Sernovas Cell Pouch, in combination w

  9. Slide 9: Phase 1/2 T1D Study Design – First Cohort

    Slide 9: Phase 1/2 T1D Study Design – First Cohort

    Phase 1/2 T1D Study Design – First Cohort Patients with Type 1 Diabetes and Hypoglycemia Unawareness Trial Overview • Open label, single-arm, single-center trial (n=7) • Insulin-dependent T1D patients with hypoglycemia unawareness Study • Cell Pouch implant followed by two sequential human donor isl

  10. Slide 10: Phase 1/2 T1D Study Interim Results – First Cohort

    Slide 10: Phase 1/2 T1D Study Interim Results – First Cohort

    Phase 1/2 T1D Study Interim Results – First Cohort ADA Presentation June 2022 • Surgical implantation of the Cell Pouch was found to be well tolerated with a favorable safety profile • All patients who had favorable immunosuppression achieved complete insulin independence • First three transplanted

  11. Slide 11: Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2

    Slide 11: Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2

    Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2 Advancing With A Higher Capacity Cell Pouch Product • Cohort 1 (6 patients) o Patients demonstrated a clear safety profile for Cell Pouch System o Established threshold for islet dose and density optimization o Cohort 1 update coming at Americ

  12. Slide 12: Abundant Supply of iPSC Insulin Producing Islet Clusters

    Slide 12: Abundant Supply of iPSC Insulin Producing Islet Clusters

    Abundant Supply of iPSC Insulin Producing Islet Clusters • Secured exclusive option on exclusive global license for Evotec’s ethically derived iPSC insulin producing islet clusters for use with Sernova’s Cell Pouch System or alone with other technologies • Access to unlimited supply of insulin-produ

  13. Slide 13: Sernova & Evotec iPSC Manufacturing Process/ Patient Experience

    Slide 13: Sernova & Evotec iPSC Manufacturing Process/ Patient Experience

    Sernova & Evotec iPSC Manufacturing Process/ Patient Experience 13

  14. Slide 14: iPSC-derived Islet-Like Clusters with Long-Term Antidiabetic Efficacy

    Slide 14: iPSC-derived Islet-Like Clusters with Long-Term Antidiabetic Efficacy

    iPSC-derived Islet-Like Clusters (ILCs) with Long-Term Antidiabetic Efficacy Robust, durable normalization of glycemic control in diabetic mice Efficient normalization of random fed glucose Circulating hC-peptide by kidney capsule-implanted ILCs Evotec GMP manufacturing site near Modena/Italy • We h

  15. Slide 15: Combining High Quality iPSC-Derived ILCs with a Clinically Proven Device

    Slide 15: Combining High Quality iPSC-Derived ILCs with a Clinically Proven Device

    Combining High Quality iPSC-Derived ILCs with a Clinically Proven Device Evotec ILCs with Sernova Cell PouchTM • The Sernova Cell PouchTM is a pre- implanted, vascularized device providing an optimal environment for therapeutic cell function1 − Accessible/retrievable implantation site • Sernova has

  16. Slide 16: Excellent Anti-Diabetic Activity of ILCs in the Cell Pouch

    Slide 16: Excellent Anti-Diabetic Activity of ILCs in the Cell Pouch

    Excellent Anti-Diabetic Activity of ILCs in the Cell PouchTM Rapid normalization of glycemic control with human islet-like potency Efficient normalization of random fed glucose Robust circulating hC-peptide levels Efficient glucose mouse glucose setpoint clearance and no hypoglycemias in oGTT (8 wee

  17. Slide 17: Excellent Anti-Diabetic Activity of an ILC/Cell Pouch Combination

    Slide 17: Excellent Anti-Diabetic Activity of an ILC/Cell Pouch Combination

    Excellent Anti-Diabetic Activity of an ILC/Cell Pouch™ Combination Summary • We have set up a scalable GMP manufacturing workflow from GMP iPS cells to ILCs, yielding a high beta cell fraction drug product − ILCs are cryopreserved at a late intermediate stage − Endocrine differentiation is complete

  18. Slide 18: Conformal Coating Technology – for Immune Protection

    Slide 18: Conformal Coating Technology – for Immune Protection

    Conformal Coating Technology – for Immune Protection • ‘Shrink wrap’ properties • Thin biocompatible cross-linked allows volume of transplanted polymer hydrogel coating that cells into the Cell Pouch to be surrounds therapeutic cells Conformal Coating – unaffected University of Miami / Sernova Colla

  19. Slide 19: Cell Pouch System for Hypothyroidism & Hemophilia A

    Slide 19: Cell Pouch System for Hypothyroidism & Hemophilia A

    Cell Pouch System for Hypothyroidism & Hemophilia A Therapeutic Benefits & Estimated Market Hypothyroidism Hemophilia A ➔ ➔ 20,000 patients across North America and EU ➔ 150,000 thyroidectomies performed annually in the US alone $10B orphan indication Estimated ➔ $2.2B market opportunity Market Size

  20. Slide 20: Upcoming Catalysts

    Slide 20: Upcoming Catalysts

    Upcoming Catalysts Anticipated Milestones and Data 2023 • Immune protection update H1 2023 • US Phase 1/2 T1D second cohort patient enrollment update H1 2023 • US Phase 1/2 T1D first cohort clinical update Q2 2023 • US Phase 1/2 T1D second cohort clinical update Q4 2023 • FDA interactions regarding

  21. Slide 21: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    Slide 21: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH Business Development Investor Relations Dr. Philip Toleikis Head Office Christopher Barnes VP, Investor Relations 1.519.858.5184 700 Collip Circle, Ste 114 philip.toleikis@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.com Tel:

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks